Robert Malone tied to Multi-Billion Dollar Leidos and MIT Labs contracts
On August 19, 2015, Leidos Incorporated announced that they had been awarded a $4.3 Billion contract from the Department of Defense.
RESTON, Va., Leidos, a national security, health and engineering solutions company, was awarded a prime contract by the Department of Defense (DoD) to provide an off-the-shelf electronic health record solution, integration activities and deployment across the Military Health System. The contract, known as the Defense Healthcare Management System Modernization (DHMSM) program, is an initiative designed to modernize the military's healthcare system in a meaningful way, enabling patients and clinicians to capture and share health data that can improve the continuity and quality of care for 9.6 million active military, their families, and their beneficiaries.
About Leidos
Leidos began as Science Applications International Corp (SAIC) in 1969 in San Diego, CA, founded by John Robert Beyster. An article written in 2007 in Vanity Fair by Barlett and Steele described a "revolving door" between the Pentagon and SAIC and a close association with the CIA.
“If the C.I.A. needs an outside expert to quietly check whether its employees are using their computers for personal business, it calls on SAIC.”
“Much to the embarrassment of a company entrusted with some of the nation's most precious secrets, its San Diego offices were mysteriously burgled in January of 2005. A censored San Diego police-department report reveals the basic outline. The report notes that the building "is patrolled byDOD certified security" and that ‘the interior lights are on motion sensors and would have been activated by the suspects.’ Nevertheless, burglars managed to break into SAIC's headquarters, pry open 13 private offices, and walk out with one desktop-computer hard drive and four laptops. By SAIC's account, the computers contained personal data on thousands of present and past employees, presumably including the company's many former C.I.A. operatives, N.S.A. executives, and Pentagon officials. To date, the burglary remains unsolved.”
Leidos merged with Lockheed Martin's IT sector in August 2016 to become the largest Information Technology (IT) Services provider for the U.S. Department of Defense. Lockheed Martin valued the deal at $4.6 Billion. Leidos valued the deal at $5.0 Billion.
Lockheed Martin, of Bethesda, MD, reported their merger in an August 2016 press release :
"This strategic transaction enhances our competitive posture in our core aerospace and defense markets and increases the value we deliver to our stockholders," said Lockheed Martin Chairman, President and CEO Marillyn Hewson. "As we position our company for the future, this action will enable us to focus our business growth strategy, align our technology investments and increase the value we deliver to customers worldwide."
Leidos trades on the New York Stock Exchange under the symbol LDOS. Leidos' stock has performed well since their merger with Lockheed Martin's IT sector.
In a report dated May 17, 2021, reporting results from a clinical study on Famotidine, Celecoxib and Dexamethason on SARS-CoV-2, Robert Malone listed a conflict of interest with Leidos and MIT Laboratories. Malone's company, RW Malone MD LLC, was a "subcontractor" to Leidos and a "consultant" to MIT Laboratories.
“Author Robert Malone was employed by RW Malone MD LLC, performing as a consultant to MIT Lincoln Laboratories, and subcontractor to Leidos, and Quantum Leap Healthcare Collaborative (QLHC) under contracts or MCDC consortium agreements issued by the US Department of Defense (DoD), Defense Threat Reduction Agency (DTRA), and the Joint Science and Technology Office (JSTO) of the Chemical and Biological Defense Program (CBDP) under the Discovery of Medical countermeasures Against Novel Entities (DOMANE) initiative. The consultant work support for this manuscript has been provided under Air Force Contract No. FA8702-15-D-0001, and for Leidos and QLHC under MCDC-2015-003 and MCDC2013-001. Dr. Malone reports personal fees and other from MIT Lincoln Laboratories/RW Malone MD LLC during the conduct of the study; COVID-related compensation outside the submitted work includes personal fees and other from Leidos/RW Malone MD LLC,”
Malone did not disclose the amounts he has been paid by Leidos or MIT Laboratories. In a lengthy Curriculum Vitae listing Malone's work experiences, patents, academic history, and accomplishments, Malone made no mention of either Leidos Incorporated or MIT Laboratories.
Contract FA870215D0001 was awarded to MIT Laboratories. It is described as "Indefinite Delivery Contract" in GovTribe, with a potential value around $25 Billion. MIT Lincoln Laboratories is located on Hanscom Air Force Base in Bedford, Massachusetts.
“FA870215D0001 is a Cost No Fee Federal Contract IDV Award. It was awarded to Massachusetts Institute Of Technology on Apr 28, 2015. The indefinite delivery contract is funded by the Electronic Systems Center (DOD - USAF - AFMC). The potential value of the award is $25,020,352,398.00. The NAICS Category for the award is 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology). The PSC Category is AC61 - R&D- Defense System: Electronics/Communication Equipment (Basic Research)”
I cannot find details on contracts MCDC-2015-003 or MCDC-2013-001, but "MCDC" appears to refer to Medical CBRN Defense Consortium. They say the are "Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures." Their website says that they have received 84 awards for around $8 Billion.
Malone told Joe Rogan that he "was infected at the end of February, because I was attending a MIT conference on drug discovery and artificial intelligence." An artificial intelligence program or programs appear to have been made available to Malone under the consulting and subcontracting contracts that he listed. "I'm the one who originally discovered famotadine as an agent because I was self-treating myself after I got infected with agents that we had identified through the computer modeling. My lungs were burning until I took famotodine and that relieved that."
The MIT conference that Malone attended on artificial intelligence drug modeling appears to be dated February 27-28 at MIT. The AP reported that after the MIT conference, Malone posted to his LinkedIn page that he'd taken famotidine, but the precise date that Malone posted this information to LinkedIn is unclear.
“By late February, Malone was convinced of famotidine’s safety and efficacy as a COVID-19 drug -- so much so that, when he contracted the disease, he took the drug himself. He reported on his LinkedIn page that he’d figured out the proper dose and became ‘the first to take the drug to treat my own case.’"
It is unclear how Malone could have contracted "COVID" so quickly in 2020. The first confirmed case of "COVID" in the United States was in Snohomish County, Washington, on January 20, 2020, just north of Seattle, from a man who had recently returned from Wuhan, China. Malone claims to have been called by a colleague of his, Michael Callahan, from Wuhan on January 04, 2020, but it is unclear if Malone and Callahan met before the late February 2020 date.
Michael Callahan reported to Malone that he had identified famotidine in Wuhan as a potential treatment for "COVID." According to numerous press reports, Malone seems to claim that he identified famotidine through computer programs, and not the phone call from Michael Callahan. Concerns have been raised that the famotidine trials intentionally used resources that should have been used for Ivermectin trials. I believe that these concerns are well-founded. The financial incentives alone are staggering.
Malone claims to be the first to describe mRNA vaccine theory and has patents on numerous related technologies. Pfizer-BioNech's "COVID-19" mRNA vaccines were given Emergency Use Authorizations in late 2020 the United States. In 2021, Pfizer-BioNtech's mRNA vaccine had revenue of around $36 Billion in 2021; Moderna had mRNA vaccine revenue around $18 Billion; J&J was around $2 Billion.
Ivermectin is an off-patent product.
Charles Wright